Clinical utility of laboratory developed mass spectrometry assays for steroid hormone testing
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Journal of mass spectrometry and advances in the clinical lab - 28(2023) vom: 25. Apr., Seite 13-19 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
French, Deborah [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 10.02.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jmsacl.2023.01.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352659874 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352659874 | ||
| 003 | DE-627 | ||
| 005 | 20231226054233.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jmsacl.2023.01.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1175.xml |
| 035 | |a (DE-627)NLM352659874 | ||
| 035 | |a (NLM)36756146 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a French, Deborah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical utility of laboratory developed mass spectrometry assays for steroid hormone testing |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.02.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ART, assisted reproductive technology | |
| 650 | 4 | |a CAP, College of American Pathologists | |
| 650 | 4 | |a CDC, Centers for Disease Control and Prevention | |
| 650 | 4 | |a CRP, C-reactive protein | |
| 650 | 4 | |a Endocrinology | |
| 650 | 4 | |a FDA, US Food and Drug Administration | |
| 650 | 4 | |a GC–MS, gas chromatography-mass spectrometry | |
| 650 | 4 | |a Immunoassay | |
| 650 | 4 | |a LC-MS/MS | |
| 650 | 4 | |a LC-MS/MS, liquid chromatography-tandem mass spectrometry | |
| 650 | 4 | |a Mass spectrometry | |
| 650 | 4 | |a NIST, National Institutes of Science and Technology | |
| 650 | 4 | |a RIA, radioimmunoassay | |
| 650 | 4 | |a RMP, Reference Measurement Procedure | |
| 650 | 4 | |a SRM, Standard Reference Material | |
| 650 | 4 | |a Sensitivity | |
| 650 | 4 | |a Specificity | |
| 650 | 4 | |a Steroid hormones | |
| 650 | 4 | |a VALID, Verifying Accurate Leading-edge IVCT Development Act of 2022 | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of mass spectrometry and advances in the clinical lab |d 2021 |g 28(2023) vom: 25. Apr., Seite 13-19 |w (DE-627)NLM330609548 |x 2667-145X |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g day:25 |g month:04 |g pages:13-19 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jmsacl.2023.01.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |b 25 |c 04 |h 13-19 | ||